New pill targets Hard-to-Treat cancers in early human trial
NCT ID NCT07561554
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental oral drug called HSK42360-Na in 159 adults with advanced solid tumors that have a specific genetic change (BRAF V600 mutation). The main goals are to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug is shrinking tumors or slowing the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HSK42360-Na (oral drug)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific BRAF V600 mutation.
- What could go wrong
- This is an early Phase 1 trial with only 159 participants, so it is too soon to know if the drug works or is safe. Side effects are unknown, and the drug may not shrink tumors or improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS (PHASE 1) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Beijing TianTan Hospital,Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100070, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.